Cocrystal Pharma (NASDAQ: COCP) grants 16,410 stock options to director

Rhea-AI Filing Summary

Cocrystal Pharma director Anthony J. Japour reported a new equity award. On January 9, 2026, he received non-qualified stock options to purchase 16,410 shares of Cocrystal Pharma common stock at an exercise price of $1.1 per share under the company’s 2025 Equity Incentive Plan. These options were approved by the Compensation Committee and reported as directly owned.

The options vest over time: one-half becomes exercisable on January 9, 2027, and the remaining half vests in eight equal quarterly installments beginning March 31, 2027, as long as he continues to serve as a director on each vesting date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Japour Anthony J

(Last) (First) (Middle)

19805 N. CREEK PARKWAY

(Street)

BOTHELL WA 98011

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cocrystal Pharma, Inc. [ COCP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)(1)	$1.1	01/09/2026		A		16,410		(1)	01/09/2036	Common Stock	16,410	$0	16,410	D

Explanation of Responses:

1. The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date.

	/s/ Anthony Japour	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Cocrystal Pharma (COCP) report for Anthony J. Japour?

Cocrystal Pharma reported that director Anthony J. Japour received a grant of 16,410 non-qualified stock options to buy common shares, effective January 9, 2026.

What is the exercise price of the new Cocrystal Pharma (COCP) stock options?

The non-qualified stock options granted to director Anthony J. Japour have an exercise price of $1.1 per share.

How do the new stock options for Cocrystal Pharma (COCP) director vest?

For the 16,410 options, half vests on January 9, 2027, and the remaining half vests in eight equal quarterly installments starting March 31, 2027, subject to his continued service as a director.

Under which plan were the Cocrystal Pharma (COCP) options granted to Anthony J. Japour?

The options were granted under Cocrystal Pharma’s 2025 Equity Incentive Plan and are subject to the company’s standard Non-Qualified Stock Option Agreement.

Is the Cocrystal Pharma (COCP) option grant to Anthony J. Japour exempt from Section 16(b)?

Yes. The filing states the non-qualified stock option grant is exempt from Section 16(b) under Rule 16b-3 because it was approved by the Compensation Committee of the Board of Directors.